Opaleye Management as of March 31, 2024
Portfolio Holdings for Opaleye Management
Opaleye Management holds 51 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 13.9 | $61M | 6.7M | 9.10 | |
| Harrow Health (HROW) | 11.9 | $52M | 3.9M | 13.23 | |
| Tg Therapeutics (TGTX) | 7.9 | $35M | 2.3M | 15.21 | |
| Keros Therapeutics (KROS) | 5.6 | $24M | 368k | 66.20 | |
| Rhythm Pharmaceuticals (RYTM) | 5.1 | $22M | 515k | 43.33 | |
| Catalyst Pharmaceutical Partners (CPRX) | 3.7 | $16M | 1.0M | 15.94 | |
| Arvinas Ord (ARVN) | 3.1 | $14M | 330k | 41.28 | |
| Iovance Biotherapeutics (IOVA) | 3.0 | $13M | 897k | 14.82 | |
| Jasper Therapeutics Com New (JSPR) | 2.9 | $13M | 436k | 29.36 | |
| Edgewise Therapeutics (EWTX) | 2.8 | $12M | 665k | 18.24 | |
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $11M | 344k | 31.86 | |
| Codexis (CDXS) | 2.5 | $11M | 3.1M | 3.49 | |
| Protara Therapeutics Com Stk (TARA) | 2.5 | $11M | 2.7M | 4.01 | |
| Acelyrin (SLRN) | 2.4 | $11M | 1.6M | 6.75 | |
| Eton Pharmaceuticals (ETON) | 2.1 | $9.2M | 2.4M | 3.75 | |
| Trevi Therapeutics (TRVI) | 2.1 | $9.1M | 2.6M | 3.45 | |
| Lyell Immunopharma (LYEL) | 1.7 | $7.5M | 3.4M | 2.23 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.7 | $7.5M | 315k | 23.65 | |
| Ventyx Biosciences (VTYX) | 1.6 | $7.1M | 1.3M | 5.50 | |
| Intellia Therapeutics (NTLA) | 1.6 | $7.0M | 255k | 27.51 | |
| Compass Therapeutics (CMPX) | 1.4 | $6.3M | 3.2M | 1.98 | |
| Xoma Corp Del Com New (XOMA) | 1.4 | $6.0M | 250k | 24.05 | |
| Liquidia Corporation Com New (LQDA) | 1.3 | $5.8M | 395k | 14.75 | |
| Vaxcyte (PCVX) | 1.3 | $5.8M | 85k | 68.31 | |
| Nyxoah S A SHS (NYXH) | 1.0 | $4.3M | 320k | 13.49 | |
| Savara (SVRA) | 1.0 | $4.3M | 855k | 4.98 | |
| Syros Pharmaceuticals Com New (SYRS) | 1.0 | $4.2M | 788k | 5.35 | |
| Urogen Pharma (URGN) | 0.9 | $4.1M | 270k | 15.00 | |
| Revance Therapeutics (RVNC) | 0.9 | $3.9M | 785k | 4.92 | |
| Applied Therapeutics (APLT) | 0.8 | $3.7M | 1.8M | 2.07 | |
| Relmada Therapeutics (RLMD) | 0.8 | $3.5M | 759k | 4.65 | |
| Protagonist Therapeutics (PTGX) | 0.7 | $3.3M | 113k | 28.93 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $3.2M | 8.0M | 0.40 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.7 | $3.2M | 200k | 15.76 | |
| Allakos (ALLK) | 0.7 | $3.1M | 2.4M | 1.26 | |
| Gossamer Bio (GOSS) | 0.7 | $2.9M | 2.4M | 1.18 | |
| Ibio Com New (IBIO) | 0.6 | $2.8M | 680k | 4.06 | |
| Verastem Com New (VSTM) | 0.6 | $2.5M | 211k | 11.80 | |
| Aligos Therapeutics (ALGS) | 0.4 | $1.6M | 1.6M | 0.98 | |
| Context Therapeutics (CNTX) | 0.4 | $1.5M | 1.1M | 1.38 | |
| Precigen (PGEN) | 0.3 | $1.4M | 948k | 1.45 | |
| Larimar Therapeutics (LRMR) | 0.3 | $1.3M | 174k | 7.59 | |
| Fulcrum Therapeutics (FULC) | 0.3 | $1.2M | 130k | 9.44 | |
| Morphosys Sponsored Ads (MOR) | 0.3 | $1.2M | 65k | 18.14 | |
| Glaukos (GKOS) | 0.2 | $809k | 8.6k | 94.29 | |
| Pmv Pharmaceuticals (PMVP) | 0.2 | $802k | 472k | 1.70 | |
| Biodesix (BDSX) | 0.2 | $765k | 535k | 1.43 | |
| Regulus Therapeutics (RGLS) | 0.1 | $491k | 170k | 2.88 | |
| Design Therapeutics (DSGN) | 0.1 | $456k | 113k | 4.03 | |
| Repare Therapeutics Ord (RPTX) | 0.1 | $318k | 68k | 4.71 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.0 | $210k | 210k | 1.00 |
